Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Potential value of circulating endothelial cells for the diagnosis and treatment of COVID-19

Xuchang Zhang\textsuperscript{a,b}, Man Jiang\textsuperscript{a,b}, Jianshe Yang\textsuperscript{a,c,*}

\textsuperscript{a} Third Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen, China
\textsuperscript{b} Department of Oncology, Longgang District People's Hospital, Shenzhen, China
\textsuperscript{c} Shanghai Tenth People's Hospital, Tongji University, Shanghai, China

ARTICLE INFO

Article history:
Received 21 January 2021
Received in revised form 29 April 2021
Accepted 1 May 2021

Keywords:
SARS-CoV-2
COVID-19
Endothelial cell
Diagnosis
Treatment

ABSTRACT

The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has been a formidable global challenge. As yet, there are very few drugs to treat this infection and no vaccine is currently available. It has gradually become apparent that coronavirus disease 2019 (COVID-19) is not a simple disease involving a single organ; rather, many vital organs and systems are affected. The endothelium is one target of SARS-CoV-2. Damaged endothelial cells, which break away from organs and enter the bloodstream to form circulating endothelial cells, were recently reported as putative biomarkers for COVID-19. Modulation of the expression level of sphingosine-1 phosphate via sphingosine kinase activation can control endothelial cell proliferation and apoptosis. As such, it may be possible to obtain a sensitive and specific diagnosis of the severity of COVID-19 by assessing the absolute number and the viable/apoptotic ratio of circulating endothelial cells. Furthermore, a focus on the endothelium could help to develop a strategy for COVID-19 treatment from the perspective of endothelial protection and repair.

© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread throughout the world. To date, there have been more than 33 million confirmed cases of coronavirus disease 2019 (COVID-19) and more than one million deaths. At the onset of the pandemic, COVID-19 was considered to be a mono-organ disease involving lesions; however, the pulmonary system, gastrointestinal system, kidney, heart and liver have now been identified as targets of SARS-CoV-2 infection (Cheung et al., 2020; Puelles et al., 2020). The endothelium has also been implicated (Varga et al., 2020). A recent study (Guervilly et al., 2020) identified a possible correlation between increased levels of circulating endothelial cells (CECs), which are the decidual endothelial cells from the injured organs or tissues circulating in blood, and the severity of COVID-19. The CEC levels in patients with COVID-19 who required intensive care unit (ICU) treatment were significantly higher compared with patients who did not need ICU treatment. Additionally, the study found a strong relationship between disease severity and the extent of endothelial injury; as such, the CEC level was postulated as a putative biomarker for the severity of COVID-19. Another study reported that the viable/apoptotic CEC ratio was significantly different in patients with COVID-19, although the absolute number of CECs was not significantly different compared with healthy controls (Mancuso et al., 2020). Furthermore, a fraction of CECs are associated with endothelial progenitor cells, which can be infected by SARS-CoV-2. However, as stem cells do not express specific receptors or limited areas of the cell membrane are covered with target receptors, these features limit direct contact and cross-talk between the virus and stem cells (Bagheri et al., 2021). This contradiction means that there is a need to consider the potential infectious mechanism cautiously, especially in the clinical transplant setting from patients with COVID-19.

The endothelium is one of the largest organs in the body; its primary function as a barrier depends on its homeostasis. A recent study demonstrated that patients with COVID-19 have a higher risk of severe outcomes when they have hypertension or diabetes, which can cause endothelial damage (Levi et al., 2020). Endothelial cells in children typically have a more complete structure and they function better compared with those in adults; consequently, endothelial tissue in children is more resistant to viral attack (Hepponstall et al., 2017). Adverse effects of COVID-19, such as hypercoagulation and vascular damage, rarely occur in children with the disease (Ludvigsson, 2020). On the contrary, researchers (Rauch et al., 2020) provided the results of a functional assay demonstrating a direct effect of dysregulation of immune response.
on endothelial damage in patients with COVID-19, and declared that the endothelial damage is associated with immunopathology and may occur in parallel with intracellular SARS-CoV-2 infection. This is direct evidence with diagnostic value of endothelial damage correlated with COVID-19.

The above findings imply that the absolute number of CECs is closely related to the severity of COVID-19, and the viable/apoptotic CEC ratio differs significantly between patients with COVID-19 and healthy controls. To some extent, CECs should be considered as a potential biomarker for COVID-19, based on their number and classification.

Many registered clinical trials for COVID-19 have been conducted, such as for antiviral and antimalarial treatment (Lythgoe and Middleton, 2020), but very few have found a reduction in overall mortality or viral load (Cao et al., 2020). Cystic fibrosis transmembrane conductance regulator (CFTR) has been found to maintain the stability of lung endothelium (Tsai and Han, 2016). CFTR dysfunction can increase the permeability of endothelial cells and may aggravate lung inflammation. Sphingosine-1 phosphate (S1P) is a sphingosine derivative which has five subtypes (S1P1–S1P5) with diverse expression levels modulated by sphingosine kinase (SphK, including SphK1 and SphK2). S1P regulates various biofunctions, including stimulation of cell proliferation by SphK1 and promotion of apoptosis of injured cells by SphK2 (Tsai and Han, 2016), and has been proven to ameliorate the negative effect of CFTR dysfunction. By modulating the expression level of S1P via the activation of SphK, the proliferation (stimulated by SphK1) and apoptosis (promoted by SphK2) of endothelial cells can be controlled (Mohammed and Harikumar, 2017). Endothelial homeostasis is maintained through these two pathways, making it more resistant to viral and bacterial invasion. Hence, physicians should aim to maintain endothelial function and ameliorate endothelial damage in patients to prevent SARS-CoV-2 infection and reduce the severity of COVID-19, particularly until there is a material breakthrough in SARS-CoV-2 vaccine and drug development.

A focus on the endothelium and endothelial cells provides the opportunity to obtain a sensitive and specific diagnosis of the severity of COVID-19 by assessing the absolute number and the viable/apoptotic ratio of CECs. Furthermore, this focus could aid in a COVID-19 treatment strategy from the perspective of endothelial protection and repair.

Author contributions

JSY conceptualized the study, XCY collected and analysed the data. JSY, MJ and XCY interpreted the results. JSY and XCY drafted the manuscript. JSY finalized the manuscript. All authors read and approved the final version of the manuscript.

Conflicts of interest

None declared.

Funding

This work was supported by the Special Fund for Economic and Scientific Development in Longgang District, Shenzhen City, Guangdong Province (No. LGKCYLWS2020043).

Ethical approval

Not required.

Acknowledgements

The authors wish to thank Dr Xigang Jing, a senior researcher at the Medical College of Wisconsin, Milwaukee, WI, USA, who provided academic support regarding endothelial physiology.

References

Bagheri HS, Karimpour M, Heidarzadeh M, Rajabi H, Sokullu E, Rahbarghazi R. Does the global outbreak of COVID-19 or other viral diseases threaten the stem cell reservoir inside the body? Stem Cell Rev Rep 2021;17:214–30.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787–99.

Cheung KS, Hung IFN, Chan PPP, Lung KC, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology 2020;159:81–95.

Cuervillo C, Burtey S, Sabatier F, Cauchois R, Lano G, Abdili E, et al. Circulating endothelial cells as a marker of endothelial injury in severe COVID-19. J Infect Dis 2020;222:1789–93.

Heponstall M, Chan A, Monagle P. Anticoagulation therapy in neonates, children and adolescents. Blood Cells Mol Dis 2017;67:41–7.

Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020;7:e438–40.

Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088–95.

Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci 2020;41:363–82.

Mancuso P, Gidaro A, Gregato G, Raveane A, Cremoinesi P, Quarna J, et al. Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases. J Thromb Haemost 2020;18:2744–50.

Mohammed S, Harikumar KB. Sphingosine 1-phosphate: a novel target for lung disorders. Front Immunol 2017;8:296.

Puelles VC, Lütgehobermann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multinuclear and retinal tropism of SARS-CoV-2. N Engl J Med 2020;383:590–2.

Rauch A, Dupont A, Coutaz J, Caplan M, Staessens S, Moussa M, et al. Endotheliopathy is induced by plasma from critically ill patients and associated with organ failure in severe COVID-19. Circulation 2020;142:1881–4.

Tsai HC, Han MH. Sphingosine-1-Phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmune and inflammation. Drugs 2016;76:1067–79.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417–8.